Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 562Carcinoma, Non-Small-Cell Lung 482Ovarian Neoplasms 326Lung Neoplasms 203Fallopian Tube Neoplasms 152Neoplasms 150Triple Negative Breast Neoplasms 125Esophageal Neoplasms 125Stomach Neoplasms 121Neoplasm Metastasis 119Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Uterine Cervical Neoplasms 79Head and Neck Neoplasms 77Esophageal Squamous Cell Carcinoma 77Recurrence 48Adenocarcinoma of Lung 47Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 31Pancreatic Neoplasms 29Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Colorectal Neoplasms 25

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Melanoma × Paclitaxel × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡